Vertex Study Shows Undetectable Hepatitis
Associated Press
(05.22.06)
On Monday, Vertex Pharmaceuticals reported good results for its hepatitis C drug candidate in all of the subjects tested in a mid-stage clinical trial. Among the 12 subjects taking the firm's drug VX-950 in combination with ribavirin and pegylated interferon alfa-2a, all had their virus reduced to undetectable levels after 28 days of treatment. After 12 more weeks, 11 patients continued to have no detectable HCV.